Clinical Trial Update: A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Pegsitacianine, an intraoperative fluorescence imaging agent, for detecting lung malignancies has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Pegsitacianine (Pegsitacianine)

Snippet

Sponsor: OncoNano Medicine, Inc. | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-11-08